https://www.thebodypro.com/category/efavirenz-sustiva-stocrin/tag/women

The Latest

Promo Image

This Week in HIV Research: The Science of Risk

Traditional factors vs. HIV-specific factors in non-communicable complications; frailty and fracture risk among women; lipid measurements and coronary risks; new data on efavirenz and birth defects.

Efavirenz Might Decrease Effectiveness of the Vaginal Contraceptive Ring Img

Efavirenz Might Decrease Effectiveness of the Vaginal Contraceptive Ring

Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.

Promo Image

Similar Efficacy and a Few Gender-Related Differences in Side Effects With Rilpivirine Versus Efavirenz at 96 Weeks

Rilpivirine (RPV) did not show teratogenicity risk in pre-clinical studies and is therefore FDA pregnancy category B, nor does it interact with the oral contraceptives norethindrone and ethinyl estradiol. For these reasons, it could be a useful optio...

Promo Image

Efavirenz Significantly Reduces Levels of Some Oral Contraceptives

A PK study evaluated the effect of co-administration of EFV 600 mg on an ethinylestradiol (EE) and norgestimate (NGM)-containing oral contraceptive (OC).

This was an open-label, 3-period, single-sequence study conducted in healthy female volunteers....